MERIBANK BIOTECH CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.15 TWD | +0.13% |
|
+0.66% | +0.13% |
| 21/03 | Meribank Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Meribank Biotech Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2023 |
|---|---|
| Capitalization 1 | 2,392 |
| Enterprise Value (EV) 1 | 2,026 |
| P/E ratio | -19.1 x |
| Yield | - |
| Capitalization / Revenue | 10.2 x |
| EV / Revenue | 8.65 x |
| EV / EBITDA | -18.5 x |
| EV / FCF | -169 x |
| FCF Yield | -0.59% |
| Price to Book | 4.09 x |
| Nbr of stocks (in thousands) | 62,776 |
| Reference price 2 | 38.10 |
| Announcement Date | 21/03/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 217.4 | 161 | 194.4 | 163.1 | 180.1 | 234.3 |
| EBITDA 1 | 4.588 | -45.26 | -58.56 | -86.11 | -98.08 | -109.4 |
| EBIT 1 | -7.837 | -57.41 | -70.11 | -97.22 | -109.8 | -123.2 |
| Operating Margin | -3.61% | -35.67% | -36.07% | -59.62% | -60.95% | -52.55% |
| Earnings before Tax (EBT) 1 | -9.347 | -59.9 | -54.46 | -99.19 | -103.2 | -129.9 |
| Net income 1 | -9.347 | -59.9 | -54.46 | -99.19 | -102.1 | -125.3 |
| Net margin | -4.3% | -37.22% | -28.01% | -60.83% | -56.7% | -53.49% |
| EPS 2 | -0.1788 | -1.139 | -1.034 | -1.644 | -1.627 | -1.995 |
| Free Cash Flow 1 | 29.03 | -23.01 | -27.46 | -55.04 | -43.73 | -11.96 |
| FCF margin | 13.35% | -14.29% | -14.13% | -33.75% | -24.28% | -5.1% |
| FCF Conversion (EBITDA) | 632.74% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 20/03/19 | 24/03/20 | 26/03/21 | 31/03/22 | 14/03/23 | 21/03/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 196 | 133 | 27.4 | 233 | 162 | 365 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 29 | -23 | -27.5 | -55 | -43.7 | -12 |
| ROE (net income / shareholders' equity) | -1.81% | -12.9% | -13.3% | -20.5% | -19.5% | -22.6% |
| ROA (Net income/ Total Assets) | -0.72% | -5.3% | -6.16% | -7.25% | -7.65% | -8.07% |
| Assets 1 | 1,296 | 1,130 | 884.3 | 1,369 | 1,335 | 1,554 |
| Book Value Per Share 2 | 9.360 | 8.260 | 7.260 | 9.340 | 7.510 | 9.320 |
| Cash Flow per Share 2 | 1.170 | 1.050 | 0.9800 | 3.060 | 1.360 | 5.630 |
| Capex 1 | 6.44 | 5.28 | 7.32 | 7.21 | 4.15 | 5.8 |
| Capex / Sales | 2.96% | 3.28% | 3.76% | 4.42% | 2.31% | 2.48% |
| Announcement Date | 20/03/19 | 24/03/20 | 26/03/21 | 31/03/22 | 14/03/23 | 21/03/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +0.13% | 83.24M | |
| +16.73% | 84.15B | |
| -25.71% | 74.14B | |
| -0.35% | 26.77B | |
| -10.77% | 17.15B | |
| +0.82% | 16.83B | |
| -0.78% | 15.21B | |
| +71.06% | 13.3B | |
| +76.76% | 12.99B | |
| -25.61% | 12.79B |
- Stock Market
- Equities
- 4724 Stock
- Financials Meribank Biotech Co., Ltd
